SUTRO BIOPHARMA, INC. (STRO): restructuring charge — Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027

SUTRO BIOPHARMA, INC.

Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.
Expected cash runway extended into at least mid-2027 due to restructuring and milestone payments.
Initial clinical data from STRO-004 (Tissue Factor-targeting exatecan ADC) expected in 2026.
Restructuring costs estimated at $4.1-4.3 million, with majority paid in Q4 2025.
Company plans to initiate clinical studies for at least one additional ADC program beyond STRO-004.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $4.1million to $4.3 million (approximately one-third).

Type: restructuring
Charge: approximately $4.1million to $4.3 million
Headcount: approximately one-third

Exact text from the filing

As part of the corporate restructuring, the Company plans to reduce its workforce by approximately one-third. The total cash payments and costs related to the further prioritization of the ADC programs and reducing the workforce are estimated to be approximately $4.1million to $4.3 million

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-223434

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.